A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
Inclusion Criteria:
Exclusion Criteria:
eMediUSA@emdserono.com888-275-7376
service@emdgroup.com+49 6151 72 5200
St. Petersburg, Florida 33701-4553, United States
West Palm Beach, Florida 33401, United States
Sterling Heights, Michigan 48098, United States
White Plains, New York 10601, United States
Ciudad Autonoma Buenos Aires, C1417DTB, Argentina
Salzburg, 5020, Austria
Toronto, Ontario M5G 2M9, Canada
Wuhan, Hubei 430060, China
Hangzhou, Zhejiang 310000, China
Saint Priest En Jarez, Pays de la Loire Region 42270, France
Paris, 75013, France
Hong Kong, 00000, Hong Kong
Sakai-shi, Osaka 590-0197, Japan
Kitaadachi-gun, Saitama 362-0806, Japan
Krakow, 31-501, Poland
Daegu, Gyeongsangnam-do 700-721, South Korea
Seoul, 03722, South Korea
Aberdeen, Grampian Region AB25 2ZN, United Kingdom